Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 7/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 6/20 | 1.00 |
| ▸ | SCN1A | P35498 | 3/20 | 1.00 |
| ▸ | SCN2A | Q99250 | 3/20 | 1.00 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 7/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.71 |
| ▸ | THPO | P40225 | 4/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | FPR2 | P25090 | 2/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30306219 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A | |
| SCHEMBL6753337 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A | |
| Hydrochloric Acid SCHEMBL1844492 | 0.99 | SCN1A (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A | |
| Hydrochloric Acid SCHEMBL11629031 | 0.99 | SCN1A (1.00) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A | |
| SCHEMBL8024067 | 0.98 | CYP3A4 (0.97) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A | |
| Hydrochloric Acid SCHEMBL15720831 | 0.97 | CYP3A4 (0.94) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A | |
| Hydrochloric Acid SCHEMBL27202576 | 0.93 | SCN1A (0.89) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A | |
| SCHEMBL14516834 | 0.90 | CYP3A4 (0.82) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A | |
| SCHEMBL4263470 | 0.88 | CYP3A4 (0.78) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A | |
| SCHEMBL27975068 | 0.87 | CYP3A4 (0.80) | CYP3A4CYP1A2CYP2C19CYP2C9SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825173-B1 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES | CHILDRENS MEDICAL CENTER (US) | 2018-10-10 | — | — | EP | claimed |
| WO-2010035047-A1 | BINARY COMPOSITIONS COMPRISING AN NO-DONOR AND AN A-SMASE INHIBITOR FOR THE TREATMENT OF RESPIRATORY DISEASES | PHARMAPATENTS GLOBAL LTD. (GB) | 2010-04-01 | — | — | WO | claimed |
| EP-0305008-A2 | Tumor or cancer cell killing therapy and agents useful therefor | OXI-GENE, INC. (US) | 1989-03-01 | — | — | EP | claimed |
| US-20240245703-A1 | TOPICAL APPLICATION OF AGENTS TO REDUCE SUN SENSITIVITY AND IMPROVE TOPICAL PHOTODYNAMIC THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-25 | — | — | US | disclosed |
| US-20240130367-A1 | PLANT GROWTH PROMOTERS | UNIVERSITY OF DURHAM (GB) | 2024-04-25 | — | — | US | disclosed |
| EP-4266883-A1 | PLANT GROWTH PROMOTERS | University of Durham (GB) | 2023-11-01 | — | — | EP | disclosed |
| CN-116916750-A | plant growth promoter | 杜伦大学 | 2023-10-20 | — | — | CN | disclosed |
| US-11654149-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654149-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2023053097-A1 | TOPICAL APPLICATION OF AGENTS TO REDUCE SUN SENSITIVITY AND IMPROVE TOPICAL PHOTODYNAMIC THERAPY | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2022136838-A1 | PLANT GROWTH PROMOTERS | UNIVERSITY OF DURHAM (GB) | 2022-06-30 | — | — | WO | disclosed |
| WO-1998050065-A2 | THE USE OF BIOLOGICALLY ACTIVE SUBSTANCES FOR INFLUENCING THE EXTRACELLULAR AREA OF SENSORY CELLS AND METHOD FOR CONTROLLING THE ADMINISTRATION OF ACTIVE SUBSTANCES AND DEVICE USED THEREIN | ECKMILLER MARION SANGSTER (DE) | 1998-11-12 | — | — | WO | disclosed |
| EP-0781335-A1 | CLONING AND CHARACTERIZING OF GENES ASSOCIATED WITH LONG-TERM MEMORY | COLD SPRING HARBOR LABORATORY (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0729356-A1 | USE OF NITRIC OXIDE SYNTHASE INHIBITORS IN THE TREATMENT OF AUTOIMMUNE DISEASES | DUKE UNIVERSITY MEDICAL CENTER (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1996011270-A9 | CLONING AND CHARACTERIZING OF GENES ASSOCIATED WITH LONG-TERM MEMORY | — | 1996-07-11 | — | — | WO | disclosed |
| WO-1996011270-A1 | CLONING AND CHARACTERIZING OF GENES ASSOCIATED WITH LONG-TERM MEMORY | COLD SPRING HARBOR LABORATORY (US) | 1996-04-18 | — | — | WO | disclosed |
| WO-1995013805-A1 | USE OF NITRIC OXIDE SYNTHASE INHIBITORS IN THE TREATMENT OF AUTOIMMUNE DISEASES | DUKE UNIVERSITY MEDICAL CENTER (US) | 1995-05-26 | — | — | WO | disclosed |
| US-5340565-A | Administering an n-substituted benzamide to activate adenosine diphosphate ribosyl transferase to cytolysis | OXI-GENE, INC. (US) | 1994-08-23 | — | — | US | disclosed |
| US-5104858-A | Administering trans-flupenthiyol with doxorubicin; lack of antipsychotic activity reduces side effects | YALE UNIVERSITY (US) | 1992-04-14 | — | — | US | disclosed |
| EP-0361485-A2 | A method of sensitizing multidrug resistant cells to antitumor agents | YALE UNIVERSITY (US) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654149-B2 | Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies | CALM1, RACK1, RRBP1 | CYP3A4 4828/4885CYP1A2 4636/4885CYP2C19 4833/4885 |
| US-20240130367-A1 | PLANT GROWTH PROMOTERS | MYCBP, GLB1, GUSB | CYP3A4 3021/4885CYP1A2 1310/4885CYP2C19 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.